Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
November 01, 2022 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted...
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
September 06, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and...
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
October 10, 2019 06:38 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate,...
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
April 16, 2019 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
August 16, 2018 06:15 ET
|
Emergent BioSolutions
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus...
CEPI vergibt Vertrag im Wert von bis zu 36 Mio. US-Dollar zur Entwicklung eines Impfstoffs gegen das Lassa-Virus an Profectus BioSciences und Emergent BioSolutions
August 16, 2018 06:15 ET
|
Emergent Biosolutions, Inc.
OSLO, Norwegen, BALTIMORE und GAITHERSBURG, Maryland, USA, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (die Coalition for Epidemic Preparedness Innovations) gab heute eine neue Kooperation mit Profectus...
Emergent BioSolutions übernimmt Spezialimpfstoffunternehmen PaxVax
August 13, 2018 11:59 ET
|
Emergent Biosolutions, Inc.
Hinzufügung von zwei umsatzgenerierenden, von der FDA zugelassenen Impfstoffen, die gegen Cholera und Typhus schützen, beide mit dualem MarktpotenzialErweiterung der Entwicklungspipeline durch einen...
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
August 13, 2018 11:59 ET
|
Emergent BioSolutions
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
August 09, 2018 06:30 ET
|
Emergent BioSolutions
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by...